专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06565880B2 Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea 有权
标题翻译： 1-（5-叔丁基-2-对甲苯基-2H-吡唑-3-基）-3- [4-（2-吗啉-4-基 - 乙氧基） - 萘-1-基] ] - 脲
公开(公告)号：US06565880B2
公开(公告)日：2003-05-20
申请号：US09902822
申请日：2001-07-11
申请人： Michael Cappola , George W. Gereg , Susan Way
发明人： Michael Cappola , George W. Gereg , Susan Way
IPC分类号： A61K914
CPC分类号： B82Y5/00 , A61K9/2018 , A61K9/2077 , A61K31/5377 , A61K47/6951
摘要： A formulation comprising, and process for preparing, improved oral dosage forms of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, a chemical entity with anti-inflammatory properties. Granulation of 1-(5-tert-but l-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea within specified ranges provides improved dissolution of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and oral bioavailability, as well as content uniformity. Incorporation into the formulation of an aqueous soluble inclusion compound capable of forming a complex with 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, such as beta-cyclodextrin provides enhanced stability of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, in particular in highly ionic environments. Chipping and disintegration of tablets containing more than about 10% betacyclodextrin can be prevented by applying a polymeric coat to the surface of the tablet at a temperature below 40° C.
摘要翻译：包含改善口服剂型1-（5-叔丁基-2-对甲苯基-2H-吡唑-3-基）-3- [4-（2-吗啉-4-基 - 乙氧基） - 萘-1-基] - 脲，具有抗炎特性的化学物质。 1-（5-叔丁基-2-对 - 甲苯基-2H-吡唑-3-基）-3- [4-（2-吗啉-4-基 - 乙氧基） - 萘-1-基] - 脲在1-（5-叔丁基-2-对甲苯基-2H-吡唑-3-基）-3- [4-（2-吗啉-4-基 - 乙氧基） - 萘-1-基] - 脲和口服生物利用度，以及含量均匀性。加入能够与1-（5-叔丁基-2-对甲苯基-2H-吡唑-3-基）-3- [4-（2-吗啉-4-基）乙氧基） - 萘-1-基] - 脲如β-环糊精提供了增强的1-（5-叔丁基-2-对甲苯基-2H-吡唑-3-基）-3 - [4-（2-吗啉-4-基 - 乙氧基） - 萘-1-基] - 脲，特别是在高离子环境中。通过在低于40℃的温度下将片剂的表面施加聚合物涂层，可以防止包含超过约10％的β-环糊精的片剂的碎裂和崩解。

2. 发明申请

US20070099832A1 Combination Therapy with p38 MAP Kinase Inhibitors and their Pharmaceutical Compositions 审中-公开
标题翻译：联合治疗与p38 MAP激酶抑制剂及其药物组合物
公开(公告)号：US20070099832A1
公开(公告)日：2007-05-03
申请号：US11539376
申请日：2006-10-06
申请人： Stefan SIMIANER , Pascal Bilbault , Michael Cappola , Susan Way
发明人： Stefan SIMIANER , Pascal Bilbault , Michael Cappola , Susan Way
IPC分类号： A61K38/17 , A61K31/5377 , A61K31/573 , A61K31/522 , A61K31/66 , A61K31/65 , A61K31/60 , A61K31/59 , A61K31/4745 , A61K31/192
CPC分类号： A61K39/395 , A61K2300/00
摘要： The present invention relates to pharmaceutical combinations therapies based on p38 kinase inhibitors and another active ingredient, pharmaceutical compositions comprising such combinations, processes for preparing them and their use in the treatment of cytokine mediated diseases.
摘要翻译：本发明涉及基于p38激酶抑制剂和另一活性成分的药物组合疗法，包含这些组合的药物组合物，其制备方法及其在治疗细胞因子介导的疾病中的用途。

3. 发明申请

US20050148555A1 Methods of treating COPD and pulmonary hypertension 审中-公开
标题翻译：治疗COPD和肺动脉高压的方法
公开(公告)号：US20050148555A1
公开(公告)日：2005-07-07
申请号：US10921448
申请日：2004-08-19
申请人： Abhya Gupta , Philippe Iacono , Linda Kelash-Cannavo , Jeffrey Madwed , Jung-Yong Park , Susan Way , Mehran Yazdanian
发明人： Abhya Gupta , Philippe Iacono , Linda Kelash-Cannavo , Jeffrey Madwed , Jung-Yong Park , Susan Way , Mehran Yazdanian
IPC分类号： A61K31/192 , A61K31/415 , A61K31/505 , A61K31/506 , A61K31/513 , A61K31/5375 , A61K31/5377 , A61K31/557 , A61K31/573 , A61K31/58 , A61K31/60 , A61K45/06
CPC分类号： A61K45/06 , A61K31/505 , A61K31/506 , A61K31/5375 , A61K31/5377
摘要： Disclosed are methods of treating COPD and Pulmonary Hypertension using p38 Map Kinase inhibitors in combination with one or more other active ingredients.
摘要翻译：公开了使用p38 Map Kinase抑制剂与一种或多种其它活性成分组合治疗COPD和肺高血压的方法。

4. 发明授权

US06808721B2 Methods for coating pharmaceutical core tablets 有权
标题翻译：药用核心片剂的涂敷方法
公开(公告)号：US06808721B2
公开(公告)日：2004-10-26
申请号：US10282383
申请日：2002-10-29
申请人： Michael Cappola , George W. Gereg , Susan Way
发明人： Michael Cappola , George W. Gereg , Susan Way
IPC分类号： A61K928
CPC分类号： B82Y5/00 , A61K31/5377 , A61K47/6951
摘要： A formulation comprising, and process for preparing, improved oral dosage forms of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, a chemical entity with anti-inflammatory properties. Granulation of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea within specified ranges provides improved dissolution of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and oral bioavailability, as well as content uniformity. Incorporation into the formulation of an aqueous soluble inclusion compound capable of forming a complex with 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, such as beta-cyclodextrin provides enhanced stability of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, in particular in highly ionic environments. Chipping and disintegration of tablets containing more than about 10% betacyclodextrin can be prevented by applying a polymeric coat to the surface of the tablet at a temperature below 40° C.
摘要翻译：包含改善口服剂型1-（5-叔丁基-2-对甲苯基-2H-吡唑-3-基）-3- [4-（2-吗啉-4-基 - 乙氧基） - 萘-1-基] - 脲，具有抗炎特性的化学物质。 1-（5-叔丁基-2-对甲苯基-2H-吡唑-3-基）-3- [4-（2-吗啉-4-基 - 乙氧基） - 萘-1-基] - 脲在特定范围内提供1-（5-叔丁基-2-对甲苯基-2H-吡唑-3-基）-3- [4-（2-吗啉-4-基 - 乙氧基） - 萘 -1-基] - 脲和口服生物利用度，以及含量均匀性。加入能够与1-（5-叔丁基-2-对甲苯基-2H-吡唑-3-基）-3- [4-（2-吗啉-4-基）乙氧基） - 萘-1-基] - 脲如β-环糊精提供了增强的1-（5-叔丁基-2-对甲苯基-2H-吡唑-3-基）-3 - [4-（2-吗啉-4-基 - 乙氧基） - 萘-1-基] - 脲，特别是在高离子环境中。通过在低于40℃的温度下将片剂的表面施加聚合物涂层，可以防止包含超过约10％的β-环糊精的片剂的碎裂和崩解。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式